$328 Million is the total value of Opaleye Management Inc.'s 43 reported holdings in Q2 2019. The portfolio turnover from Q1 2019 to Q2 2019 was 62.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CDXS | Sell | CODEXIS INC | $24,881,000 | -17.8% | 1,350,000 | -8.5% | 7.58% | -9.6% |
| AXGN | Sell | AXOGEN INC | $17,820,000 | -23.1% | 900,000 | -18.2% | 5.43% | -15.3% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $11,791,000 | +13.3% | 125,000 | -3.8% | 3.59% | +24.7% |
| CERC | Sell | CERECOR INC | $11,176,000 | -16.8% | 2,185,536 | -5.0% | 3.41% | -8.4% |
| TGTX | Sell | TG THERAPEUTICS INC | $9,948,000 | -9.4% | 1,150,000 | -15.8% | 3.03% | -0.3% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $6,991,000 | -11.4% | 310,000 | -8.8% | 2.13% | -2.5% |
| FGEN | Sell | FIBROGEN INC | $6,777,000 | -37.7% | 150,000 | -25.0% | 2.07% | -31.4% |
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $3,568,000 | -37.8% | 1,140,000 | -1.1% | 1.09% | -31.6% |
| VKTX | Sell | VIKING THERAPEUTICS INC | $3,320,000 | -31.1% | 400,000 | -17.5% | 1.01% | -24.2% |
| AIMT | Sell | AIMMUNE THERAPEUTICS INC | $2,708,000 | -26.6% | 130,000 | -21.2% | 0.82% | -19.2% |
| FENC | Sell | FENNEC PHARMACEUTICALS INC | $1,180,000 | -61.4% | 295,000 | -53.2% | 0.36% | -57.4% |
| CRNX | Sell | CRINETICS PHARMACEUTICALS INC | $900,000 | -45.8% | 36,000 | -50.7% | 0.27% | -40.4% |
| LJPC | Exit | LA JOLLA PHARMACEUTICAL CO | $0 | – | -60,000 | -100.0% | -0.11% | – |
| KURA | Exit | KURA ONCOLOGY INC | $0 | – | -25,200 | -100.0% | -0.12% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -180,000 | -100.0% | -0.19% | – |
| ESTA | Exit | ESTABLISHMENT LABS HLDGS INC | $0 | – | -50,000 | -100.0% | -0.33% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -115,000 | -100.0% | -0.62% | – |
| LQDA | Exit | LIQUIDIA TECHNOLOGIES INC | $0 | – | -225,000 | -100.0% | -0.71% | – |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -1,000,000 | -100.0% | -0.73% | – |
| SWAV | Exit | SHOCKWAVE MED INC | $0 | – | -92,100 | -100.0% | -0.85% | – |
| ACOR | Exit | ACORDA PHARMACEUTICALS | $0 | – | -265,000 | -100.0% | -0.98% | – |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -200,000 | -100.0% | -1.09% | – |
| ABEO | Exit | ABEONA THERAPEUTICS INC | $0 | – | -560,000 | -100.0% | -1.14% | – |
| RTRX | Exit | RETROPHIN INC | $0 | – | -205,000 | -100.0% | -1.28% | – |
| HZNP | Exit | HORIZON PHARMA PLC | $0 | – | -185,000 | -100.0% | -1.35% | – |
| DERM | Exit | DERMIRA INC | $0 | – | -400,000 | -100.0% | -1.50% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -550,000 | -100.0% | -2.02% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INC | $0 | – | -105,000 | -100.0% | -2.13% | – |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -1,825,000 | -100.0% | -2.58% | – |
| NVTA | Exit | INVITAE CORP | $0 | – | -440,000 | -100.0% | -2.85% | – |
| CMTA | Exit | CLEMENTIA PHARMACEUTICALS INC | $0 | – | -400,130 | -100.0% | -2.89% | – |
| ASND | Exit | ASCENDIS PHARMA A Ssponsored adr | $0 | – | -95,000 | -100.0% | -3.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-31 |
| 13F-HR/A | 2024-05-29 |
| 4 | 2024-05-23 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.